Envelope surface glycoprotein gp120
|
env
|
HIV-1 Env (gp120) binds to CD209 (DC-SIGN), which activates NFKB1 (NF-kB), MAPK1 (ERK1/2), and MAPK14 (p38) |
PubMed
|
|
env
|
HIV-1 CN54 Env (gp120) induces phosphorylation of RELA (p65), IRF3, MAPK14 (p38), and MAPK1 (ERK1/2) through TLR4 induction in monocyte derived macrophages; anti-TLR4 antibodies could inhibit this activation |
PubMed
|
|
env
|
HIV-1 gp120-induced release of IL-6 is regulated by p38 MAPK, IkappaBalpha, and p65 NF-kappaB activation in primary human monocyte-derived dendritic cells |
PubMed
|
|
env
|
HIV-1 gp120-induced release of IL-10 depends on the activation of Raf-1 along with NF-kappaB p65 in immature dentritic cells |
PubMed
|
|
env
|
HIV-1 gp120 co-localizes with the p65 subunit of NF-kappaB in human female genital epithelial cells |
PubMed
|
|
env
|
Inhibition of NRF2 by siRNA results in increased NOX2, NFkappaB (p65/p50), TNF-alpha, and MMP-9 proteins in astrocytes exposed to HIV-1 gp120 |
PubMed
|
Envelope transmembrane glycoprotein gp41
|
env
|
Exposure of TZM-bl-2 cells to HIV gp41 increases RELA (NFkappaB subunit p65) nucelar translocation |
PubMed
|
|
env
|
The binding of soluble TLR2 to HIV-1 MA, CA, or gp41 inhibits the nuclear translocation of NFKB p65 subunit and downregulates IL-8 and CCR5 expression, leading to inhibition of HIV-1 infection in cells |
PubMed
|
|
env
|
The HIV-1 gp41 cytoplasmic domain-induced NFkappaB activation requires TAK1, RelA, and NEMO proteins |
PubMed
|
Nef
|
nef
|
HIV-1 Nef induces RELA (NFKB p65) translocation/nuclear localization |
PubMed
|
|
nef
|
HIV-1 and SIVcpz Nef proteins enhance TNF-alpha, IKK-beta, and RelA/p65-induced NF-kappaB activation in 293T cells |
PubMed
|
|
nef
|
Knockdown of the p50 and p65 subunits of NF-kappaB by siRNA shows significant reduction of CCL5 levels, suggesting that NF-kappaB is involved in Nef-mediated upregulation of CCL5 |
PubMed
|
Tat
|
tat
|
HIV-1 Tat increases binding of RELA (p65) to the NF-kappaB consensus site |
PubMed
|
|
tat
|
HIV-1 Tat protein activates RELA (p65), MAP kinases ERK1/2 and p38, and PKC-bII in a TLR4-dependent manner in human monocytes |
PubMed
|
|
tat
|
HIV-1 Tat relocalizes PRKCQ (PKC-theta) and RELA (NFkB) to the nucleus of Jurkat T cells that stably express Tat |
PubMed
|
|
tat
|
HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat |
PubMed
|
|
tat
|
HIV-1 Tat induces phosphorylation of RELA (p65) in CRT-MG human astroglioma cells |
PubMed
|
|
tat
|
HIV-1 Tat increases nuclear localization of RELA (p65) in Huvec and EA.hy926 cells |
PubMed
|
|
tat
|
HIV-1 Tat induces phosphorylation of RELA (p65) in HUVEC and EA.hy926 cells |
PubMed
|
|
tat
|
HIV-1 Tat activates RELA (NF-kappaB) in a TLR4 dependent manner |
PubMed
|
|
tat
|
HIV-1 Tat treatment induces phosphorylation of NFKB p65 (RELA) at position Ser-536 in human mesenchymal stem cells |
PubMed
|
|
tat
|
The gene expression of RELA is significantly upregulated in both clade B and clade C Tat treated SK-N-MC neuroblastoma cells |
PubMed
|
|
tat
|
HIV-1 Tat enhances the NFkappaB activity by inhibiting IkappaB-alpha binding to p65 RelA |
PubMed
|
|
tat
|
Curcumin and celastrol attenuate HIV-1 Tat-induced p65/NFKappaB phosphorylation and IKK phosphorylation |
PubMed
|
|
tat
|
HIV-1 Tat-mediated transcriptional activation of the HIV-1 LTR promoter requires NFkappaB binding sites in the promoter and involves the activation of NFkappaB by Tat |
PubMed
|
|
tat
|
HIV-1 Tat-mediated upregulation of CCL5 involves JAK2/3, AKT2/3, p38delta, NF-kappaB (p65/p50), C/EBP alpha/gamma, and AP-1 proteins |
PubMed
|
|
tat
|
HIV-1 Tat-induced upregulation of miR-222 is a NF-kappaB p65-dependent manner |
PubMed
|
|
tat
|
HIV-1 Tat-mediated upregulation of ICAM-1 expression involves MEK1/2, JNK, and p38 MAPK proteins and downstream IKK2/NF-kappaB(p65) signaling pathways |
PubMed
|
|
tat
|
HIV-1 Tat downregulates the expression of p65 NFkappaB in CD4+ T cells, which may contribute to the reduced levels of nuclear hTERT in Tat exposed cells |
PubMed
|
|
tat
|
HIV-1 Tat upregulates miR-34a in TZM-bl cells, which results in downregulation of SIRT1 protein expression and activity and induction of NFkappaB p65 acetylation by MiR-34a |
PubMed
|
|
tat
|
HIV-1 Tat enhances the NFkappaB activity and promotes the transcriptional activation of MIP-1alpha by interacting with IkappaB-alpha and p65 RelA |
PubMed
|
|
tat
|
HIV-1 Tat induces the acetylation of the NFkappaB p50 subunit as well as the p50/p65 complex by p300, causing an increase in NFkappaB DNA binding activity and in the rate of transcription |
PubMed
|
|
tat
|
Inhibition of HIV-1 Tat-mediated transactivation of the HIV-1 LTR promoter by NFkappaB/Rel inhibitors correlates with their inhibitory activities on the RelA subunit of the NFkappaB complex, indicating an interaction of Tat with RelA |
PubMed
|
|
tat
|
A compound in curry known as Curcumin inhibits HIV-1 Tat-mediated long terminal repeat transactivation by reversing Tat-induced dissociation of HDAC1 from LTR and by reducing the binding of p65/NFKappaB to LTR promoted by Tat |
PubMed
|
|
tat
|
HIV-1 Tat increases the p65 RelA affinity binding to DNA through association with p65 RelA |
PubMed
|
|
tat
|
HIV-1 Tat and morphine treatment significantly increase the levels of phosphorylated p65 NF-kappaB in human hepatocellular carcinoma cells |
PubMed
|
|
tat
|
HIV-1 Tat inhibits the LPS-induced activation of NFkappaB p65 via its induction of IkappaBalpha expression, which results in retention of NFkappaB p65 in the cytosol |
PubMed
|
|
tat
|
HIV-1 Tat has been shown to bind NFkappaB in vitro in gel shift, GST-pull down and affinity matrix assays |
PubMed
|
|
tat
|
HIV-1 Tat recruits P/CAF to the integrated HIV-1 LTR promoter causing the acetylation of histones, which in turn leads to the recruitment the p65 subunit of NFkappaB to the promoter |
PubMed
|
|
tat
|
NFAT-1 negatively regulates HIV-1 Tat-mediated transactivation of the HIV-1 LTR by competing with NFkappaB for its binding to the LTR, thereby blocking the interaction of NFkappaB with Tat |
PubMed
|
|
tat
|
HIV-1 Tat enhances tumor necrosis factor-induced activation of NFkappaB by downregulating manganese-dependent superoxide dismutase (MnSOD) |
PubMed
|
|
tat
|
NFkappaB tethers the p160 nuclear receptor co-activator GRIP1 to the HIV-1 LTR promoter, thereby regulating the full activation of this promoter by HIV-1 Tat |
PubMed
|
|
tat
|
HIV-1 Tat activates NFkappaB through the cellular interferon-inducible, double-stranded RNA dependent protein kinase, PKR |
PubMed
|
|
tat
|
p56-lck plays a critical role in the activation of NFkappaB by HIV-1 Tat |
PubMed
|
|
tat
|
Activation of NFkappaB by HIV-1 Tat leads to a reduction in adenylyl cyclase activity and an inhibition of cAMP synthesis |
PubMed
|
|
tat
|
Activation of NFkappaB by HIV-1 Tat is inhibited by Nitric Oxide |
PubMed
|
|
tat
|
HIV-1 Tat activates NFkappaB, causing the induction of CD95 ligand, CD69, iNOS, MCP-1, IL-2, IL-6, IL-8, IL-10, TNF-alpha, VCAM-1, ICAM-1, E-selectin, and MMP-9, as well as monocyte adhesion, cellular activation and angiogenesis |
PubMed
|
|
tat
|
HIV-1 Tat upregulates c-rel and RelA transcription factor binding to the CD28-responsive element in the IL-8 promoter, leading to super-induction of IL-8 |
PubMed
|
Vpr
|
vpr
|
HIV-1 Vpr activates RELA (NFkappaB) signaling following internalization into PEL cells |
PubMed
|
|
vpr
|
HIV-1 Vpr-induced upregulation of CCL5 requires p50 and p65 subunits of NF-kappaB, p38delta MAPK, Akt-2 and Akt-3, and AP-1 transcription factor in HIV-1 Vpr transfected astrocytes |
PubMed
|
|
vpr
|
HIV-1 Vpr induces phosphorylation of Rel A (p65) and relocates Rel A from the cytoplasm into the nucleus |
PubMed
|
|
vpr
|
HIV-1 Vpr inhibits the phosphorylation of NFkappaB p65 subunit in response to TNF-alpha treatment |
PubMed
|
|
vpr
|
HIV-1 Vpr decreases in nuclear translocation of NF-KappaB/p65 protein and p65 DNA-binding activity in multidrug-resistant human colorectal cancer cells in a time-dependent manner |
PubMed
|
|
vpr
|
HIV-1 Vpr induces HIF-1alpha expression, which involves the presence of Sp1 and the p65 subunit of NFkappaB transcription factors |
PubMed
|
|
vpr
|
HIV-1 Vpr inhibits the nuclear translocation of Rel A in infected T cells |
PubMed
|
|
vpr
|
Data suggests that HIV-1 Vpr acts in concert with Rel A and p300 to activate HIV transcription, possibly by Vpr effects on Cdc2 kinase activity |
PubMed
|
Vpu
|
vpu
|
HIV-1 Vpu inhibits nuclear translocation of RelA/p65 and the SS/AA mutations in the DSGxxS motif of Vpu largely abolish this activity in HeLa cells |
PubMed
|
|
vpu
|
HIV-1 Vpu and TASK-1 decreases HIV-1 transcription by suppressing unintegrated HIV-1 DNA, which is inhibited by overexpression of RelA |
PubMed
|
capsid
|
gag
|
The binding of soluble TLR2 to HIV-1 MA, CA, or gp41 inhibits the nuclear translocation of NFKB p65 subunit and downregulates IL-8 and CCR5 expression, leading to inhibition of HIV-1 infection in cells |
PubMed
|
matrix
|
gag
|
Exposure of TZM-bl-2 cells to HIV MA (p17) increases RELA (NFkappaB subunit p65) nuclear translocation |
PubMed
|
|
gag
|
The binding of soluble TLR2 to HIV-1 MA, CA, or gp41 inhibits the nuclear translocation of NFKB p65 subunit and downregulates IL-8 and CCR5 expression, leading to inhibition of HIV-1 infection in cells |
PubMed
|